Seagen Inc. (SGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Visitors trend2W10W9M

213.70

+7.31

(+3.54%)

At close: 04:00PM EDT

213.85

+0.15

(+0.07%)

After hours:

06:42PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Williams %R

View all chart patterns

Performance Outlook

Previous Close	206.39
Open	213.80
Bid	212.89 x 900
Ask	214.08 x 1000
Day's Range	213.20 - 214.00
52 Week Range	116.08 - 214.00
Volume	3,162,256
Avg. Volume	1,160,958

Market Cap	40.111B
Beta (5Y Monthly)	0.48
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SGEN

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Seagen Inc.
Analyst Report: Seagen Inc.Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Rating
Fair Value
Economic Moat
26 days agoMorningstar

News

The Wall Street Journal
Stocks to Watch Friday: Alibaba, Activision, Microsoft, Ford, Meta Platforms
**↗️** [**Microsoft (MSFT)**](https://www.wsj.com/market-data/quotes/MSFT), [**Activision Blizzard (ATVI)**](https://www.wsj.com/market-data/quotes/ATVI): A modified deal by the software giant to buy the videogame publisher was [cleared by the U.
- Activision Stock Hits Highs After Microsoft Deal Progress
  The Wall Street Journal
- Acquisition Watch: Time to Buy Microsoft (MSFT) or Activision Blizzard (ATVI) Stock?
  Zacks
Zacks
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.